Join to View Full Profile
6 Glen Cove Dr Ste 360Rockport, ME 04856
Phone+1 207-921-8969
Fax+1 207-910-4407
Dr. Inhorn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1994- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
Washington University in St. Louis School of MedicineClass of 1990
Certifications & Licensure
ME State Medical License 2004 - 2026
MO State Medical License 1997 - 2006
IL State Medical License 1997 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsA phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced ...Denise A. Yardley, John D. Zubkus, Brooke R. Daniel, Roger Inhorn, Cassie M. Lane
Clinical Breast Cancer. 2010-10-01 - 8 citationsPhase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung CancerDavid R. Spigel, F. Anthony Greco, Dana S. Thompson, Charles D. Webb, James R. Rubinsak
Clinical Lung Cancer. 2010-05-01 - 70 citationsThe cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent mannerKai Xia, Nishit K. Mukhopadhyay, Roger C. Inhorn, Dwayne L. Barber, P. E. Rose
Proceedings of the National Academy of Sciences of the United States of America. 1996-10-15
Press Mentions
4 Oncologists on the MoveJanuary 28th, 2022
MaineHealth Launches Comprehensive Medical Oncology Practice in Biddeford, SacoOctober 6th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
